FDA panel backs peptide additions to 503A compounding list
Enhanced Group issued a clarification highlighting a July 23-24, 2026 FDA advisory committee vote backing a legal compounding pathway for several peptides.
The vote is non-binding; formal inclusion on the FDA’s 503A bulk substances list requires notice-and-comment rulemaking expected to take months.
The company framed the move as a shift from gray-market sourcing toward regulated supply chains through licensed 503A and 503B compounding pharmacies.
Management positioned its existing pharmacy relationships and telehealth platform as enabling faster rollout if the FDA follows the recommendation.
ENHA•
